There is clinical trial data emerging using bi or tri therapy. Indeed attacking the virus on multiple fronts might be advantageous. as the data accumulates our tools will use itA recent trial in Hong Kong showed that interferon+lopinavir+ritonavir+ribavirin was better than lopinavir+ritonavir alone. Yes, we think that polypharmacy is likely to be more effective. But, DDIs and synergistic safety issues call for caution.
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.